FILER: SELICK HAROLD E TITLE: Chief Executive Officer
DATE TRANSACTION SHARES PRICE VALUE 6/3/09-6/5/09 Purchase 20,000 $1.52 $30,300
OWNERSHIP: 259,897 (Direct)
The Form 4 is filed with the Securities and Exchange Commission by insiders to report transactions in their companies' shares. Open market purchases and sales must be reported within two business days of the transaction.
Insider Data Source: The Washington Service (firstname.lastname@example.org or 301-913-5100)
Selick (CEO)and Hurd (CMO) both bought shares in the open market - listen to the ASCO presentation and you'll know why. There is noticeable excitement in their voices because the safety profile to date is better than anticipated (higher MTD acheived in mono and no dangerous toxicities in combination with either of the 4 other chemo agents thus far) and they are seeing response rates that are well beyond what approved "conventional" chemo agents have acheived. By the end of the year, they will have larger numbers to present, but I don't think the market (or potential partners) are going to wait that long. In other words, get in now or you'll be kicking yourself come Thanksgiving!
It´s almost two years since the inception of TH-302 on THLD´s pipeline after their (semi)failed attempt on Glofosfamide. I now believe THLD is more prapared than ever to give the real proof of their HAP technology and the benefits to the oncology sector should be disclosed anytime before or slightly after the the phase 2 complete enrollment with the interim results to be published before the end of this year. This is an accumulate period opportunity perhaps better than any other biotech in years.Tred as always, I agree with your positive thinking and believe this is the begining of a nice ride to double digits in record time. I´m completely convinced TH-302 is here to stay. G-luck!